Future studies will investigate whether the drug combination can slow disease progression or reverse deficits after symptoms have appeared.
CLICK HERE FOR MORE HEALTH STORIES
“This work has taken many years. But now we’re at a point where basic neuroscience discoveries are pointing toward something that could realistically move into the clinic,” Chen said.
Dr. Paul Saphier, a neurosurgeon and founder of Coaxial Neurosurgical Specialists in New Jersey, called this research an “exciting breakthrough with a huge potential impact for patients and their families.”
“We know that the buildup of the plaques related to Alzheimer’s [beta-amyloid plaques] are the result of chronic inflammation.” (iStock)
“Neurocognitive deterioration has been linked to conditions that cause inflammation within the brain — prior brain bleeds, strokes, tumors and infections,” he told Fox News Digital. “We also know that the buildup of the plaques related to Alzheimer’s [beta-amyloid plaques] are the result of chronic inflammation.”
“So, it makes sense that this combination therapy [might] help limit the production of this amyloid and thereby reduce the progression of the disease.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Saphier said the drugs’ FDA approval status is “encouraging,” as it may “ultimately ease the availability for patients, if the trial proves successful.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“I look forward to the results of this trial, as well as any future trials that look at limiting the effects of chronic inflammation within the central nervous system.”
Article source: https://www.foxnews.com/health/marijuana-compound-may-help-prevent-dementia-when-paired-common-drug